Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy

Brain, Behavior, and Immunity

Volumn 24, Issue 6, 2010, Pages 968-974

  Wang, Xin Shelley ^a   Shi, Qiuling ^a   Williams, Loretta A ^a   Mao, Li ^a   Cleeland, Charles S ^a   Komaki, Ritsuko R ^a   Mobley, Gary M ^a   Liao, Zhongxing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Inflammatory cytokines; MDASI; Mixed effect model; NSCLC; Symptom

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; ANTINEOPLASTIC AGENT; CYTOKINE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG ACCUMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LONGITUDINAL STUDY; LUNG NON SMALL CELL CANCER; M D ANDERSON SYMPTOM INVENTORY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION DOSE; SCORING SYSTEM; SLEEP DISORDER; SORE THROAT; SYMPTOM; BIOSYNTHESIS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; COST OF ILLNESS; DOSE RESPONSE; GENETICS; INFLAMMATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RADIATION RESPONSE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; COST OF ILLNESS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954219789     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.03.009     Document Type: Article

References (37)

1. Barcellos-Hoff M.H. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat. Res. 1998, 150:S109-S120.
2. Barsevick A.M., Whitmer K., Nail L.M., Beck S.L., Dudley W.N. Symptom cluster research: conceptual, design, measurement, and analysis issues. J. Pain Symptom Manage. 2006, 31:85-95.
3. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
4. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., Cole S., Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15:5534-5540.
5. Bradley J., Deasy J.O., Bentzen S., El-Naqa I. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:1106-1113.
6. Cleeland C.S. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J. Natl. Cancer Inst. Monogr. 2007, 37:16-21.
7. Cleeland C.S. Cancer-related symptoms. Semin. Radiat. Oncol. 2000, 10:175-190.
8. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Lee B.N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?. Cancer 2003, 97:2919-2925.
9. Cleeland C.S., Mendoza T.R., Wang X.S., Chou C., Harle M.T., Morrissey M., Engstrom M.C. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer 2000, 89:1634-1646.
10. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 1995, 31:1341-1346.
11. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav. Immun. 2001, 15:7-24.
12. Dodd M.J., Miaskowski C., Paul S.M. Symptom clusters and their effect on the functional status of patients with cancer. Oncol. Nurs. Forum 2001, 28:465-470.
13. Fairclough D.L., Wang X.S. Understanding the correlations between biologic and symptom measures over time. Advancing Health Outcomes Research Methods and Clinical Applications 2005, 177-190. Degnon Associates, McLean, VA. W.R. Lenderking, D.A. Revicki (Eds.).
14. Fan G., Filipczak L., Chow E. Symptom clusters in cancer patients: a review of the literature. Curr. Oncol. 2007, 14:173-179.
15. Germano G., Allavena P., Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008, 43:374-379.
16. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., Perez C.A. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 1999, 45:323-329.
17. Hart J.P., Broadwater G., Rabbani Z., Moeller B.J., Clough R., Huang D., Sempowski G.A., Dewhirst M., Pizzo S.V., Vujaskovic Z., Anscher M.S. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1448-1454.
18. Hickok J.T., Morrow G.R., Roscoe J.A., Mustian K., Okunieff P. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J. Pain Symptom Manage. 2005, 30:433-442.
19. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
20. Kirkova J., Davis M.P., Walsh D., Tiernan E., O'Leary N., LeGrand S.B., Lagman R.L., Russell K.M. Cancer symptom assessment instruments: a systematic review. J. Clin. Oncol. 2006, 24:1459-1473.
21. Lee B.N., Dantzer R., Langley K.E., Bennett G.J., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Cleeland C.S. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004, 11:279-292.
22. Liao Z.X., Komaki R.R., Thames H.D., Liu H.H., Tucker S.L., Mohan R., Martel M.K., Wei X., Yang K., Kim E.S., Blumenschein G., Hong W.K., Cox J.D. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small cell lung cancer receiving concomitant chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76:775-781.
23. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D. Analysis of repeated measures data. SAS System for Mixed Models 1996, 87-134. SAS Institute Inc., Cary, NC. R.C. Littell, G.A. Milliken, W.W. Stroup, R.D. Wolfinger (Eds.).
24. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
25. Miles D.W., Aderka D., Engelmann H., Wallach D., Balkwill F.R. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br. J. Cancer 1992, 66:1195-1199.
26. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26:971-982.
27. Patrick D.L., Ferketich S.L., Frame P.S., Harris J.J., Hendricks C.B., Levin B., Link M.P., Lustig C., McLaughlin J., Reid L.D., Turrisi A.T., Unutzer J., Vernon S.W. National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J. Natl. Cancer Inst. Monogr. 2004, 2004:9-16.
28. Preti H.A., Cabanillas F., Talpaz M., Tucker S.L., Seymour J.F., Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann. Intern. Med. 1997, 127:186-194.
29. Rube C.E., Wilfert F., Uthe D., Konig J., Liu L., Schuck A., Willich N., Remberger K., Rube C. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother. Oncol. 2004, 72:231-241.
30. Rube C.E., Wilfert F., Uthe D., Schmid K.W., Knoop R., Willich N., Schuck A., Rube C. Modulation of radiation-induced tumour necrosis factor alpha (TNF-α) expression in the lung tissue by pentoxifylline. Radiother. Oncol. 2002, 64:177-187.
31. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
32. Thavasu P.W., Longhurst S., Joel S.P., Slevin M.L., Balkwill F.R. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J. Immunol. Methods 1992, 153:115-124.
33. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9:4653-4665.
34. Wang X.S., Fairclough D.L., Liao Z., Komaki R., Chang J.Y., Mobley G.M., Cleeland C.S. Longitudinal study of the relationship between chemoradiation therapy for non-small cell lung cancer and patient symptoms. J. Clin. Oncol. 2006, 24:4485-4491.
35. Wang X.S., Shi Q., Williams L.A., Cleeland C.S., Mobley G.M., Reuben J.M., Lee B.N., Giralt S.A. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008, 113:2102-2109.
36. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., Denham J.W. Fatigue during breast radiotherapy and its relationship to biological factors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:160-167.
37. Yamamoto N., Nishimura Y., Nakagawa K., Matsui K., Fukuoka M. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2006, 58:285-291.